Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo

Autor: Claudia Asperti, Daniele Canarutto, Simona Porcellini, Francesca Sanvito, Francesca Cecere, Valentina Vavassori, Samuele Ferrari, Elisabetta Rovelli, Luisa Albano, Aurelien Jacob, Lucia Sergi Sergi, Elisa Montaldo, Francesca Ferrua, Luis Ignacio González-Granado, Vassilios Lougaris, Raffaele Badolato, Andrea Finocchi, Anna Villa, Marina Radrizzani, Luigi Naldini

Publikováno v: Molecular Therapy: Methods & Clinical Development, Vol 30, Iss , Pp 546-557 (2023)

Hyper-IgM1 is a rare X-linked combined immunodeficiency caused by mutations in the CD40 ligand (CD40LG) gene with a median survival of 25 years, potentially treatable with in situ CD4+ T cell gene editing with Cas9 and a one-size-fits-most corrective

Externí odkaz: https://doaj.org/article/95bf4664548f487685bff24201e74568

CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice

Autor: Simona Porcellini, Claudia Asperti, Stefano Corna, Eleonora Cicoria, Veronica Valtolina, Anna Stornaiuolo, Barbara Valentinis, Claudio Bordignon, Catia Traversari

Publikováno v: Frontiers in Immunology, Vol 11 (2020)

The main challenge of adoptive therapy with Chimeric Antigen Receptor modified T cells (CAR T) is the application to the field of solid tumors, where the identification of a proper antigen has emerged as one of the major drawbacks to CAR T cell treat

Externí odkaz: https://doaj.org/article/7301d7cf04b2437fadb57727709d647a

Biochemical and functional characterization of the interaction between liprin-α1 and GIT1: implications for the regulation of cell motility.

Autor: Claudia Asperti, Veronica Astro, Emanuela Pettinato, Simona Paris, Angela Bachi, Ivan de Curtis

Publikováno v: PLoS ONE, Vol 6, Iss 6, p e20757 (2011)

We have previously identified the scaffold protein liprin-α1 as an important regulator of integrin-mediated cell motility and tumor cell invasion. Liprin-α1 may interact with different proteins, and the functional significance of these interactions

Externí odkaz: https://doaj.org/article/44f66f669c674c69bab1211f629900e8

Towards Clinical Translation of Hematopoietic Cell Gene Editing for Treating Hyper-IgM Type 1

Autor: Eugenio Scanziani, Luigi Naldini, Luisa Albano, Aurelien Jacob, Anna Villa, Claudia Asperti, Pietro Genovese, Maria Carmina Castiello, Elisabetta Mercuri, Marina Radrizzani, Genni Enza Marcovecchio, Valentina Vavassori, Elena Fontana, Daniele Canarutto

Publikováno v: Blood. 138:3978-3978

Hyper-IgM Type 1 (HIGM1) is caused by mutations of CD40L, whose absence in CD4 T cells impairs signaling for B cell activation and Ig class-switching. Since unregulated CD40L expression leads to lymphoproliferations/lymphomas in the mouse model of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::624c9eeba49da1888fd4dff6791d9d19
https://doi.org/10.1182/blood-2021-148572

Mechanism of action of the tumor vessel targeting agent NGR-hTNF: Role of both NGR peptide and hTNF in cell binding and signaling

Autor: Claudia Asperti, Paola Di Matteo, Catia Traversari, Barbara Valentinis, Gian Paolo Rizzardi, Dan Zhou, Manuela Cota, Chiara Zucchelli, Simona Porcellini, Gianpiero Garau, Nilla Roberta Avanzi, Massimo Degano, Giovanna Musco

Publikováno v: 'International Journal of Molecular Sciences ', vol: 20, pages: 4511-1-4511-22 (2019)
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4511 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 18

NGR-hTNF is a therapeutic agent for a solid tumor that specifically targets angiogenic tumor blood vessels, through the NGR motif. Its activity has been assessed in several clinical studies encompassing tumors of different histological types. The dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6c511677049392198a2073d337f538
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:53926